Published in Kidney Int on February 15, 2012
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis (2015) 1.69
Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion (2014) 1.38
Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol (2012) 1.01
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials (2014) 0.87
Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am J Transplant (2013) 0.84
Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev (2015) 0.84
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation. Yonsei Med J (2015) 0.81
Mechanisms and consequences of injury and repair in older organ transplants. Transplantation (2014) 0.80
The Tao of myeloma. Blood (2014) 0.80
Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med (2014) 0.79
Late and chronic antibody-mediated rejection: main barrier to long term graft survival. Clin Dev Immunol (2013) 0.79
HLA class I: an unexpected role in integrin β4 signaling in endothelial cells. Hum Immunol (2012) 0.78
B cells with regulatory properties in transplantation tolerance. World J Transplant (2015) 0.78
B-cell-mediated strategies to fight chronic allograft rejection. Front Immunol (2013) 0.77
Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study. Xenotransplantation (2013) 0.75
Immunosuppressive Medications. Clin J Am Soc Nephrol (2015) 0.75
Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. J Am Soc Nephrol (2016) 0.75
Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation. Yonsei Med J (2017) 0.75
Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation. Pediatr Nephrol (2017) 0.75
Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13
Donors with central nervous system malignancies: are they truly safe? Transplantation (2003) 2.12
Malignancy after transplantation. Transplantation (2005) 1.92
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012. Liver Transpl (2014) 1.63
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Hand-assisted laparoscopic living-donor nephrectomy as an alternative to traditional laparoscopic living-donor nephrectomy. Am J Transplant (2002) 1.44
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
Temporary silastic mesh closure for adult liver transplantation: a safe alternative for the difficult abdomen. Liver Transpl (2007) 1.40
Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant (2007) 1.30
An initial experience and evolution of laparoscopic hepatic resectional surgery. Surgery (2004) 1.26
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation (2009) 1.25
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation (2010) 1.25
Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation (2006) 1.24
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation (2004) 1.18
Donor transmitted malignancies. Ann Transplant (2004) 1.13
Laparoscopic donor nephrectomy vs. open live donor nephrectomy: a quality of life and functional study. Clin Transplant (2005) 1.07
Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol (2005) 1.05
Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation (2008) 1.03
Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation (2013) 1.03
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation (2002) 1.03
A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant (2005) 1.02
Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant (2008) 1.01
The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol (2003) 1.00
Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant (2009) 1.00
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation (2011) 0.98
Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant (2008) 0.98
Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol (2011) 0.97
Laparoscopic liver resection. J Am Coll Surg (2005) 0.95
Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol (2012) 0.95
Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation (2011) 0.95
Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation (2004) 0.94
Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant (2005) 0.94
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation (2012) 0.92
Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum (2004) 0.92
Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg (2010) 0.90
Basic and clinical research in polyomavirus nephropathy. Exp Clin Transplant (2004) 0.90
BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol (2008) 0.90
Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant (2005) 0.90
Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons. J Plast Reconstr Aesthet Surg (2008) 0.90
Desensitization in kidney transplantation: review and future perspectives. Clin Transplant (2014) 0.90
Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. Virology (2010) 0.89
YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant (2010) 0.88
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation (2012) 0.88
Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival. Transplantation (2015) 0.87
Posttransplant malignancy. Prog Transplant (2004) 0.87
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87
Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation (2004) 0.87
Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid Redox Signal (2014) 0.86
Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit (2007) 0.86
Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int (2015) 0.85
A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation (2009) 0.83
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation (2010) 0.83
Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs (2011) 0.83
African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant (2005) 0.83
Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis. HPB (Oxford) (2014) 0.82
Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant (2010) 0.81
Polyomavirus nephropathy in kidney transplantation. Prog Transplant (2004) 0.81
Right donor nephrectomy: a comparison of hand-assisted transperitoneal and retroperitoneal laparoscopic approaches. Transplantation (2004) 0.81
Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplantation (2005) 0.81
Genotypic variation and phenotypic characterization of granzyme B gene polymorphisms. Transplantation (2009) 0.80
Incidental diagnosis of gastric cancer in transplant recipients improves patient survival. Surgery (2002) 0.80
Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant (2011) 0.79
Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int (2006) 0.79
Malignancy in pediatric transplant recipients. Semin Pediatr Surg (2006) 0.78
A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy. Transplantation (2015) 0.78
Kidney transplantation: graft monitoring and immunosuppression. World J Surg (2001) 0.78
Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. Transplantation (2013) 0.78
Steroid minimization for sirolimus-treated renal transplant recipients. Clin Transplant (2010) 0.78
Risk assessment of immunosuppressive therapy in facial transplantation. Plast Reconstr Surg (2007) 0.78
How can donors with a previous malignancy be evaluated? J Hepatol (2006) 0.77